The 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial: Study protocol for a randomized controlled trial

Trials

Volumn 13, Issue , 2012, Pages

  Park, Kyung W ^a   Park, Byoung Eun ^b   Kang, Si Hyuck ^a   Park, Jin Joo ^a   Lee, Seung Pyo ^a   Cha, Kwang S ^c   Rhew, Jay Y ^d   Jeon, Hui Kyoung ^e   Shin, Eun S ^f   Oh, Ju H ^g   Jeong, Myung Ho ^h   Kim, Sanghyun ⁱ   Hwang, Kyung Kuk ^j   Yoon, Jung Han ^k   Lee, Sung Y ^l   Park, Tae Ho ^m   Moon, Keon W ⁿ   Kwon, Hyuck Moon ^o   Chae, In Ho ^p   Kim, Hyo Soo ^a  

^a Seoul National University Hospital   (South Korea)

^b Dankook University   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

^d Presbyterian Medical Center   (South Korea)

^e Uijeongbu St Mary's Hospital   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

^g Sungkyunkwan University School of Medicine   (South Korea)

^h Chonnam National University Medical School   (South Korea)

ⁱ Seoul National University Boramae Hospital   (South Korea)

^j Chungbuk National University Hospital   (South Korea)

^k Wonju Severance Christian Hospital   (South Korea)

^l Inje University   (South Korea)

^m Dong A Medical Center   (South Korea)

ⁿ The Catholic University of Korea   (South Korea)

^o Yonsei University College of Medicine   (South Korea)

^p Seoul National University Bundang Hospital   (South Korea)

more..

Author keywords

Cilostazol; Cobalt chromium; Coronary heart disease; Everolimus eluting stent; Platinum chromium; Zotarolimus eluting stent

Indexed keywords

ACETYLSALICYLIC ACID; ALLOY; ANTITHROMBOCYTIC AGENT; CHROMIUM; CILOSTAZOL; CLOPIDOGREL; COBALT; EVEROLIMUS; PLATINUM; PRASUGREL; TICAGRELOR; ZOTAROLIMUS; CHROMIUM DERIVATIVE; DRUG DERIVATIVE; RAPAMYCIN;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; HEART FAILURE; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; INSTRUMENTATION; METHODOLOGY; PROSTHESIS; SOUTH KOREA; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; CHROMIUM; CHROMIUM ALLOYS; CORONARY STENOSIS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATINUM; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REPUBLIC OF KOREA; RESEARCH DESIGN; SINGLE-BLIND METHOD; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84859081535     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-13-29     Document Type: Article

References (26)

1. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010, 375:201-209. 10.1016/S0140-6736(09)62127-9, 20060578.
2. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ, . SPIRIT IV Investigators Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010, 362:1663-1674. 10.1056/NEJMoa0910496, 20445180, SPIRIT IV Investigators.
3. Takagi H, Umemoto T. An updated meta-analysis of randomized controlled trials of everolimus- versus paclitaxel-eluting stents. Int J Cardiol 2011, 151:354-355. 10.1016/j.ijcard.2011.05.086, 21640401.
4. Park KW, Chae IH, Lim DS, Han KR, Yang HM, Lee HY, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Jo SH, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Gwon HC, Jang YS, Kim HS. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. J Am Coll Cardiol 2011, 58:1844-1854. 10.1016/j.jacc.2011.07.031, 22018294.
5. Byrne RA, Kastrati A, Massberg S, Wieczorek A, Laugwitz KL, Hadamitzky M, Schulz S, Pache J, Fusaro M, Hausleiter J, Schömig A, Mehilli J, . ISAR-TEST 4 Investigators Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J Am Coll Cardiol 2011, 58:1325-1331. 10.1016/j.jacc.2011.06.027, 21920260, ISAR-TEST 4 Investigators.
6. de Waha A, Dibra A, Byrne RA, Ndrepepa G, Mehilli J, Fusaro M, Laugwitz KL, Massberg S, Schömig A, Kastrati A. Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. Circ Cardiovasc Interv 2011, 4:371-377. 10.1161/CIRCINTERVENTIONS.111.963256, 21791671.
7. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010, 363:136-146. 10.1056/NEJMoa1004130, 20554978.
8. Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Allocco DJ, Dawkins KD, . PLATINUM Trial Investigators A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol 2011, 57:1700-1708. 10.1016/j.jacc.2011.02.016, 21470815, PLATINUM Trial Investigators.
9. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008, 29:992-1000. 10.1093/eurheartj/ehn046, 18263931.
10. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008, 52:1128-1133. 10.1016/j.jacc.2008.06.038, 18804738.
11. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009, 119:237-242. 10.1161/CIRCULATIONAHA.108.812636, 19118249.
12. Park KW, Jeon KH, Kang SH, Oh IY, Cho HJ, Lee HY, Kang HJ, Park SK, Koo BK, Oh BH, Park YB, Kim HS. Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study). Am J Cardiol 2011, 108:1556-1563. 10.1016/j.amjcard.2011.07.012, 21880289.
13. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S, . CURRENT-OASIS 7 trial investigators Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010, 376:1233-1243. 10.1016/S0140-6736(10)61088-4, 20817281, CURRENT-OASIS 7 trial investigators.
14. James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009, 157:599-605. 10.1016/j.ahj.2009.01.003, 19332184.
15. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, . Academic Research Consortium Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007, 115:2344-2351. 10.1161/CIRCULATIONAHA.106.685313, 17470709, Academic Research Consortium.
16. Baber U, Mehran R, Sharma SK, Brar S, Yu J, Suh JW, Kim HS, Park SJ, Kastrati A, de Waha A, Krishnan P, Moreno P, Sweeny J, Kim MC, Suleman J, Pyo R, Wiley J, Kovacic J, Kini AS, Dangas GD. Impact of the everolimus-eluting stent on stent thrombosis a meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011, 58:1569-1577. 10.1016/j.jacc.2011.06.049, 21924575.
17. Stefanini GG, Serruys PW, Silber S, Khattab AA, van Geuns RJ, Richardt G, Buszman PE, Kelbæk H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, Di Mario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli AL, Gobbens P, Windecker S. The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention). J Am Coll Cardiol 2011, 57:2221-2232. 10.1016/j.jacc.2011.01.036, 21616282.
18. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009, 53:849-856. 10.1016/j.jacc.2008.11.030, 19264241.
19. Hwang SJ, Jeong YH, Kim IS, Koh JS, Kang MK, Park Y, Kwak CH, Hwang JY. The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. Thromb Res 2011, 127:23-28. 10.1016/j.thromres.2010.10.021, 21075428.
20. Oh IY, Park KW, Kang SH, Park JJ, Na SH, Kang HJ, Koo BK, Jeong YH, Hwang JY, Kwak CH, Park Y, Hwang SJ, Ko YG, Shin DJ, Jang Y, Kim HS. Association of cytochrome P450 2 C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart 2012, 98:139-144. 10.1136/hrt.2011.227272, 21700758.
21. Park KW, Park JJ, Jeon KH, Kang SH, Oh IY, Yang HM, Cho HJ, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS. Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans. Cardiovasc Ther 2012, 30:5-11. 10.1111/j.1755-5922.2010.00249.x, 21129165.
22. Jeong YH, Lee SW, Choi BR, Kim IS, Seo MK, Kwak CH, Hwang JY, Park SW. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009, 53:1101-1109. 10.1016/j.jacc.2008.12.025, 19324253.
23. Park KW, Park JJ, Lee SP, Oh IY, Suh JW, Yang HM, Lee HY, Kang HJ, Cho YS, Koo BK, Youn TJ, Chae IH, Choi DJ, Oh BH, Park YB, Kim HS. Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial. Heart 2011, 97:641-647. 10.1136/hrt.2010.216499, 21345843.
24. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 2008, 51:1181-1187. 10.1016/j.jacc.2007.11.049, 18355656.
25. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Kang SJ, Park SJ, Lee JH, Choi SW, Seong IW, Lee NH, Cho YH, Shin WY, Lee SJ, Lee SW, Hyon MS, Bang DW, Choi YJ, Kim HS, Lee BK, Lee K, Park HK, Park CB, Lee SG, Kim MK, Park KH, Park WJ, . DECLARE-LONG II Study Investigators A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol 2011, 57:1264-1270. 10.1016/j.jacc.2010.10.035, 21392640, DECLARE-LONG II Study Investigators.
26. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, Cho YS, Youn TJ, Chae IH, Choi DJ, Rha SW, Bae JH, Kwon TG, Bae JW, Cho MC, Kim HS. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 2011, 57:280-289. 10.1016/j.jacc.2010.08.631, 21232664.